2015年5月20日 · Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) made from a humanized anti-Trop-2 monoclonal antibody (hRS7) conjugated with the active metabolite of irinotecan, SN-38.

2019年2月20日 · Sacituzumab govitecan-hziy (IMMU-132; Immunomedics) is an antibody–drug conjugate in which SN-38 (an active metabolite of irinotecan), a topoisomerase I inhibitor, is coupled to the...

2021年4月21日 · A phase 1–2, single-group, basket trial (IMMU-132-01) evaluated sacituzumab govitecan monotherapy in metastatic, epithelial cancers. 21-23 In the cohort of 108 patients with metastatic triple...

Sacituzumab govitecan (IMMU‐132) is an antibody‐drug conjugate that contains the irinotecan active metabolite, SN‐38, linked to a humanized monoclonal antibody targeting trophoblast cell surface antigen 2 (Trop‐2), which is overexpressed in many solid tumors.

2017年10月1日 · Background: Sacituzumab govitecan (IMMU-132), an antitrophoblastic cell-surface antigen (anti-Trop-2) humanized antibody-SN-38 conjugate, had encouraging efficacy in the phase 1 clinical trial. This report further examines the pharmacokinetics and safety of multiple cycles of IMMU-132 at doses of 8 or 10 mg/kg in patients with diverse advanced ...

Sacituzumab govitecan-hziy (IMMU-132; Im-munomedics) is an antibody–drug conjugate in which SN-38 (an active metabolite of irinotecan), a topoisomerase I inhibitor, is coupled to the hu-

2015年4月27日 · IMMU-132 treatment of mice bearing human gastric cancer xenografts (17.5 mg/kg; twice weekly × 4 weeks) resulted in significant antitumor effects compared to that of mice treated with a nonspecific control.

The IMMU-132-01 phase I/II basket trial (NCT01631552) evaluated the safety and efficacy of SG in adult patients with various advanced epithelial cancers who had disease progression following treatment with at least one standard therapeutic regimen for their disease. Patients were enrolled regardless of their Trop-2 expression level. Safety

2017年5月30日 · Sacituzumab govitecan (IMMU-132), an antibody-drug conjugate targeting SN-38 to Trop-2 (an antigen identified in many epithelial cancers), is exhibiting promising activity in several indications. The...

BACKGROUND: Sacituzumab govitecan (IMMU-132), an anti-Trop-2 humanized antibody-SN-38 conjugate, had encouraging efficacy in the phase I clinical trial. This report further examines the pharmacokinetics and safety of multiple cycles of IMMU-132 administered at 8 or 10 mg/kg doses to patients with diverse advanced epithelial cancers.